Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR‐mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis

Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR‐mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis

Abstract Background Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) remains a significant hurdle for patients with EGFR‐mutated non‐small cell lung cancer (NSCLC), particularly those lacking the EGFRT790M. IMpower 150 study demonstrated promising effica...

Full description

Saved in:
Bibliographic Details
Main Authors: Shang‐Gin Wu, Chao‐Chi Ho, James Chih‐Hsin Yang, Shu‐Han Yu, Yen‐Feng Lin, Shu‐Chin Lin, Bin‐Chi Liao, Ching‐Yao Yang, Yen‐Ting Lin, Chong‐Jen Yu, Ya‐Ting Chuang, Wei‐Yu Liao, Kah Yi Yap, Weng Si Kou, Jin‐Yuan Shih
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:Clinical and Translational Medicine
Subjects:
anti‐angiogenesis
atezolizumab
EGFR TKI resistance
immune cell
tumour microenvironment
Online Access:https://doi.org/10.1002/ctm2.70149
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/ctm2.70149

Similar Items